TRIM22, a tripartite-motif (TRIM) protein, is upregulated upon interferon alpha (IFNa) administration to hepatitis C virus (HCV)-infected patients. However, the physiological role of TRIM22 upregulation remains unclear. Here, we describe a potential antiviral function of TRIM22's targeting of the HCV NS5A protein. NS5A is important for HCV replication and for resistance to IFNa therapy. During the first 24 h following the initiation of IFNa treatment, upregulation of TRIM22 in the peripheral blood mononuclear cells (PBMCs) of HCV patients correlated with a decrease in viral titer. This phenomenon was confirmed in the hepatocyte-derived cell line Huh-7, which is highly permissive for HCV infection. TRIM22 over-expression inhibited HCV replication, and Small interfering RNA (siRNA)-mediated knockdown of TRIM22 diminished IFNa-induced anti-HCV function. Furthermore, we determined that TRIM22 ubiquitinates NS5A in a concentration-dependent manner. In summary, our results suggest that TRIM22 upregulation is associated with HCV decline during IFNa treatment and plays an important role in controlling HCV replication in vitro.
INTRODUCTION
Hepatitis C virus (HCV) is a global problem, and according to the World Health Organization, 150 million people are currently infected. 1 HCV is an enveloped, positive-sense singlestranded RNA virus of the family Flaviviridae. 2 The viral RNA is translated as a precursor polyprotein, which is then spliced into 10 separate proteins. 3 The three structural proteins are E1, E2 and core, while p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B are the non-structural proteins. 3 HCV replication mainly occurs in hepatocytes. HCV infection is frequently not detected during the acute phase of infection, and most patients become chronically infected. 4 Some chronic HCV patients may further develop liver cirrhosis or even liver cancer. 4 Interferon alpha (IFNa) plus ribavirin is the standard therapy for HCV patients in China. 5 IFNa is a broad-spectrum anti-viral molecule and plays an important role in the anti-viral innate immune response. 6 Endogenous IFNa is induced by viruses through pattern recognition receptors, such as Toll-like receptors, RIG-I and MDA5. 7, 8 IFNa elicits anti-viral activity by binding to Heterodimer of interferon alpha receptor1(IFNAR1) and interferon alpha receptor 2 (IFNAR2) and inducing Janus-activated kinase 1 and tyrosine kinase 2, which in turn phosphorylate and thereby activate signal transducer and activator of transcription proteins 1 and 2 (STAT1 and STAT2). 9 IFN-regulatory factor 9 forms a complex with the STAT1/2 complex in the cell nucleus, leading to the upregulation of interferon-stimulated 6 These authors contributed equally to this work.
1 genes (ISGs), which are involved in biological processes such as lipid metabolism, apoptosis, inflammation and protein degradation. 9 Some ISGs affect the translation of viral proteins, such as protein kinase R. 9 IFNa may also decrease viral RNA stability by inducing 29,59-oligoadenylate synthetase during HCV treatment. 9 The tripartite motif (TRIM) family of proteins is defined by the highly conserved RBCC signature domain, which contains a RING finger domain, one or two B-Box domains, and a coiledcoil domain. 10, 11 The RING finger domain contains a specialized zinc finger and functions as a ubiquitin protein ligase, either alone or as a part of a multi-subunit E3 protein complex. The associated B-Box and coiled-coil domains are involved in protein interactions and homo/heterodimerization. TRIM proteins are involved in a variety of cellular functions, including apoptosis, transcription, differentiation and regulation of cell cycle progression. 10, 11 In addition, some TRIM proteins exhibit anti-viral activity and may be involved in innate immunity. 10, 11 Many TRIM proteins have recently emerged as IFN-induced proteins involved in various cellular processes, including cell proliferation and antiviral activities. TRIM22, also known as Staf-50, is a natural antiviral effector of HIV-1, 12 HBV 13 and influenza. 14 The dependence of the anti-viral function of TRIM22 on its ubiquitination function varies depending on the virus. 10, 11 For example, TRIM22 inhibits influenza by targeting its nucleoprotein, but also inhibits the activity of the HBV core promoter not through ubiquitination. 13 We previously determined that TRIM22 is highly upregulated in peripheral blood mononuclear cell (PBMC) samples from HCV patients treated with IFNa, as well as in Huh-7 cells treated with IFNa. 13 The function of TRIM22 was further verified by examining its effects on the HCV Huh-7-Con-1 replicon system or JFH1 virus. Here, the mechanism of TRIM22 is explored.
MATERIALS AND METHODS

Subjects and study protocol
The study was approved by the ethics committee of the 1st Hospital of Jilin University and was registered with ClinicalTrials.gov, ID NCT01434212. All enrolled subjects were hepatitis B surface antigen-negative, hepatitis B surface antigen antibody-negative and HIV antibody-negative, with no serological or histological evidence of a cause of liver disease other than HCV. Treatment consisted of standard IFNa (Recombinant Human IFNa-2b; Kaiyinyisheng Inc., Beijing, China, FDA Approval number: S20030032) plus ribavirin (Weilake, FDA Approval number: H10940157) for 48 weeks. Five million units of IFNa-2b were administered subcutaneously every other day at the clinic throughout treatment. Ribavirin was dosed at 15 mg/kg/day in two divided doses. Serum HCV RNA levels were measured using the COBAS AmpliPrep/COBAS TaqMan assay (Roche Molecular Diagnostics, Pleasanton, CA, USA) with a lower limit of quantification of 15 IU/ml. Measurements were obtained at the following time points after IFNa treatment initiation: 0 h, 12 h, 24 h, 37 h and 43 h. PBMCs were separated using GE Percoll reagent (Product Code: 17-0891-01) following the manufacturer's instructions.
Reagents and antibodies
Recombinant IFNa was purchased from eBioscience, San Diego, CA, USA. Anti-FLAG monoclonal antibody (M2) and anti-actin antibody were purchased from Sigma-Aldrich, St. Louis, MO, USA. Anti-HA monoclonal antibody was purchased from Covance. Rabbit anti-TRIM22 polyclonal antibody was purchased from Sigma (Cat. No. HPA003307).
Reverse transcription and real-time RT-PCR Total RNA was obtained using TRIzol reagent (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. Total cellular RNA (2 mg) was reverse-transcribed with SuperScript II reverse transcriptase (Life Technologies), and 2 ml of the reverse-transcribed cDNA was used in real-time RT-PCR with the 7900HTFast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and a traditional agarose gel assay. The primers used for TRIM22 detection were 59-GGTT-GAGGGGATCGTCAGTA-39 (L) and 59-TTGGAAACAGATT-TTGGCTTC-39 (R).
Plasmids
Sequences encoding TRIM22 were amplified by PCR from cDNA from Huh-7 cells challenged with IFNa for 12 h. TRIM22 and its truncation mutants were cloned into the pcDNA3.1-59-FLAG vector. PCR amplification was performed in a Mastercycler (Eppendorf, Hamburg, Germany), and PCR products were separated on 1% agarose gels and visualized by ethidium bromide staining.
The sequences of the PCR primers were as follows: 17 JFH1 full genome Huh-7 cells were generated as previously described. 18 HEK293T, Huh-7 or HCV replicon cells were cultured in DMEM (Life Technologies) supplemented with heat-inactivated fetal calf serum (10%), penicillin (100 U/ml) and streptomycin (100 mg/ml). The cells were grown at 37 uC in a humidified incubator with a 5% CO 2 atmosphere.
HEK293T cells were seeded into 6-well plates or 24-well plates for 24 h. The cells were transiently transfected using Lipofectamine (Life Technologies) according to the manufacturer's instructions. The plasmid amounts were normalized by the addition of empty plasmid.
Immunoblotting and immunoprecipitation
For immunoblotting, cells were washed with ice-cold phosphate-buffered saline and lysed with ice-cold lysis buffer containing 1.0% (v/v) Nonidet P40, 20 mM Tris-HCl pH 8.0, 10% (v/v) glycerol, 150 mM NaCl, 1 mM NaF, 2 mM sodium orthovanadate, 1 mM sodium pyrophosphate and a protease inhibitor cocktail (Roche, Basel, Switzerland). After incubation on ice for 15 min, the supernatant was obtained by centrifuging the crude lysates at 12 000 g for 15 min to remove cell debris. Total protein was separated on a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad, Berkeley, CA, USA). For immune detection, membranes were washed with TBS-T (20 mM Tris, 500 mM NaCl, 0.1% Tween 20) and blocked in a 5% powdered-milk solution in TBS-T for 1 h. After washing with TBS-T, the membranes were separately probed with anti-HA (HA1.1) (Covance, Princeton, NJ, USA) (1 : 1000), anti-FLAG M2 (1 : 1000), anti-TRIM22 (1 : 500) (Sigma) and anti-beta-actin (1 : 1000) antibodies for 1 h. Secondary peroxidase-labeled anti-rabbit or anti-mouse antibodies were incubated for 1 h at room temperature. Anti-NS5A was raised in Dr Jin Zhong's lab. Protein detection was visualized by ECL according to the manufacturer's directions (Pierce, Waltham, MA, USA).
For immunoprecipitation, total cell lysates were subjected to immunoprecipitation with 0.5 mg of mouse anti-HA (HA1.1) (Covance) monoclonal antibody or rabbit anti-TRIM22 polyclonal antibodies in 500 ml of 1% (v/v) lysis buffer. Binding between the antibody and antigen was allowed to occur at 4 uC for 2 h in suspension under constant rotation. Then, the protein A/G agarose suspension was added, and the mixture was incubated for 2 h at 4 uC with constant agitation. The immunoprecipitated complexes were washed three times with 1% IP buffer, and the proteins were eluted by adding 30 ml of 2% SDS-PAGE sample buffer, followed by boiling for 5 min. Sepharose beads were pelleted by centrifugation in a microfuge for 5 min. The supernatant containing proteins was separated by SDS-PAGE, followed by staining with mouse anti-FLAG M2 monoclonal antibody (Sigma).
siRNA TRIM22 Stealth Select RNAi (Catalog# 1299003) was purchased from Life Technologies: short interfering negative control sequence 59-UUCUCCGAACGUGUCACGUTT-39, si1 59-CA-CCAAACAUUCCGCAUAATT-39, si2 59-GGAUGCUGCAAG-UUCUUAATT-39. HEK293T cells or Huh-7 cells were transfected with the siRNA targeting TRIM22 or control siRNA (20 nM final concentration) using Lipofectamine 2000 (Life Technologies) or Lipofectamine LTX (Life Technologies) using the standard method described in the manufacturer's protocol. Empty vector was added to normalize the final plasmid amount. The degree of gene silencing was confirmed by RT-PCR or immunoblotting 24 h after transfection.
Statistical analysis
Normally distributed continuous variables were compared using t-tests. The Mann-Whitney test was used when a normal distribution was rejected (Shapiro test, P,0.05). In all cases, a P value #0.05 was considered significant. IBM SPSS V.19 software was used for statistical analysis.
RESULTS
TRIM22 is induced in PBMCs from HCV patients by Type I
IFNa treatment and is associated with a decrease in HCV titers TRIM22 is upregulated by IFNa treatment. In this study, we evaluated whether this association occurred in HCV patients who were treated with IFNa. Patient PBMCs were collected after IFNa treatment, and TRIM22 expression was analyzed by both real-time PCR and immunoblotting. A significant increase in TRIM22 expression was observed in a real-time PCR assay 12 h after the initiation of IFNa treatment (Figure 1a ). TRIM22 induction was also observed at the protein level by western blotting (Figure 1c) . Concomitantly, the HCV virus titer in the blood decreased rapidly (Figure 1b) . The change in early virus kinetics after IFNa administration suggests that TRIM22 is involved in IFNa-induced antiviral effects.
TRIM22 is upregulated in Huh-7 cells treated with IFNa
To determine whether IFNa is capable of inducing TRIM22, we examined TRIM22 expression in the Huh-7 human hepatocyte cell line after IFNa treatment. When Huh-7 cells were treated with IFNa for 6 h, TRIM22 mRNA expression increased, reaching a maximum at 18 h post-stimulation (Figure 2a) . Accordingly, western blotting with a TRIM22-specific antibody revealed that TRIM22 protein levels increased significantly after 12 h of stimulation (Figure 2b) . HCV infection triggered endogenous TRIM22 expression (Figure 2c ), albeit at lower levels than that induced by direct IFNa stimulation. Taken together, these results demonstrate that TRIM22 is induced following IFNa stimulation of Huh-7 cells.
TRIM22 is an anti-HCV molecule
We next determined whether IFNa-induced TRIM22 can suppress HCV replication. The Huh-7 cell line was transfected with the Con1 replicon genome as described previously by Lohmann et al. 17 After selection with G418, we obtained a cell line that expressed the deleted Con1 genome stably, Huh-7-Con1-rep. TRIM22 was over-expressed in Huh-7-Con1-rep cells (Figure 3a) , leading to a decrease in HCV levels of approximately 50% compared to control cells 48 h following transfection and approximately 72% at 96 h (Figure 3c ). Inhibition of HCV was also observed at the protein level by western blot assay (Figure 3b ). To suppress TRIM22 expression, two siRNAs were designed, and their knockdown efficiency was evaluated by western blotting (Figure 3d ). Cells were infected with the HCV JFH-1 virus (multiplicity of infection (MOI) of 0.1). When the infected cells were treated with control siRNA and IFNa in combination, HCV RNA was significantly decreased. By contrast, under the same conditions, si1 and si2 against TRIM22 at the same concentration as the control siRNA suppressed TRIM22 expression and subsequently inhibited IFNa treatment-mediated suppression of HCV at both the protein and RNA levels (Figure 3e and f) . Thus, TRIM22 is an anti-HCV molecule that can negatively regulate HCV replication.
TRIM22 interacts with HCV NS5A
Because TRIM22 is an anti-HCV ISG, we determined whether TRIM22 directly interacts with the proteins encoded by HCV. First, we screened all HCV proteins by co-immunoprecipitation (co-IP) (Supplementary Figure 1) , which revealed that TRIM22 specifically binds the NS5A protein (Figure 4a) . Second, the endogenous TRIM22-NS5A interaction was observed (Figure 4b ). We next identified the domain of TRIM22 that is essential for the interaction between TRIM22 and NS5A. Four truncations of TRIM22 lacking the SPRY and the coiled coil domains (A), the SPRY domain (B), the RING and B-box domains (C) or only the RING domain (D) were constructed to identify the domains required for the interaction between TRIM22 and NS5A (Figure 4c mutants A and B (which lack the SPRY domain) were unable to interact with NS5A (Figure 4d) , indicating that the SPRY domain is important for the interaction between TRIM22 and NS5A. This interaction suggests that the NS5A protein plays a role in the inhibition of HCV function by TRIM22. We also determined which domain of NS5A is essential for the interaction between TRIM22 and NS5A. NS5A contains three protein domains: Domain 1, Domain 2 and Domain 3. We created three truncations of NS5A, NS5A-D1 (Domain 1), NS5A-D12 (Domain 1 and 2) and NS5A-D23 (Domain 2 and 3) (Figure 4e ). Only NS5A-D23 did not interact with TRIM22, indicating that domain 1 is essential for the interaction between NS5A and TRIM22 (Figure 4f ). In addition, TRIM22 and NS5A colocalized in the cytoplasm of Huh-7 cells around lipid droplets (Figure 4j and Supplementary Figure 2) .
TRIM22 is an ubiquitin ligase for NS5A TRIM family members feature a common E3 ubiquitin ligase domain; thus, TRIM22 may be a ubiquitin ligase for NS5A. TRIM22 efficiently ligated ubiquitin to NS5A (Figure 5c ) and degraded NS5A in a concentration-dependent manner (Figure 5b ). MG132 blocked the TRIM22-mediated degradation of NS5A (Figure 5d ). TRIM22 does not degrade other HCV proteins, indicating that the degradation is specific for NS5A (Figure 5a ). Based on the importance of NS5A in HCV replication and the results of our study, we conclude that TRIM22 is induced by IFNa and plays a role in negatively regulating HCV replication by ligating ubiquitin to NS5A.
DISCUSSION
In the present study, upregulation of TRIM22 by IFNa was associated with a decrease in HCV titer in the blood of patients on the first day after IFNa administration. Because liver biopsy samples were not available, it is unclear whether TRIM22 was also induced in hepatocytes. Previous research 13 has demonstrated that TRIM22 is upregulated in liver cell lines, consistent with its up-regulation in PBMCs. In the present study, upregulation of TRIM22 was also observed in Huh-7 cells after IFNa treatment.
There is still no consensus on the localization of TRIM22. 19 When 293T or COS7 cells were transfected with human TRIM22 tagged with GFP, TRIM22 was localized in the cytoplasm. . TRIM22 was colocalized with NS5A in the cytoplasm. Immunofluorescence was performed IFNa using anti-TRIM22 and anti-NS5A 12 h after IFNa treatment. LD staining was conducted with bodipy dye (Life Technologies D2228). The region of co-localization is indicated in white in the figure labeled 'Co-local'. TRIM22 and NS5A were colocalized near the lipid droplet, which is reported to be important for HCV assembly. co-IP, co-immunoprecipitation; HCV, hepatitis C virus; IFN, interferon; MOI, multiplicity of infection; TRIM, tripartite motif.
IFN-a-induced TRIM22 interrupts HCV replication
By contrast, when HepG2 cells were transfected with myc-tagged TRIM22, TRIM22 was localized in the nucleus. 19, 22, 23 Moreover, in the serum-starved U2OS cell line, TRIM22 was localized in both the nucleus and cytoplasm. 19, 24, 25 Gao and colleagues observed that TRIM22 was mainly localized in the nucleus of HepG2 cells when it suppresses HBV survival. 13 The discrepancy in localization compared to our present study may be due to the different cell lines we used (Huh-7 cell lines).
The mechanism by which TRIM22 suppresses HCV replication is of substantial interest. Studies of changes in HCV kinetics during IFNa therapy have demonstrated that the dramatic decrease in viral titer on the first day of IFNa therapy is mainly caused by the inhibition of HCV replication. 26 All HCV proteins were screened for interaction with TRIM22, resulting in the sole identification of NS5A. NS5A is a viral factor that helps HCV establish a niche in the host cell by turning off the IFNa signaling pathway. 27 The sequence of a certain NS5A region, called the interferon sensitivity-determining region, 28 is highly associated with the final outcome of IFNa therapy. Furthermore, experimental evidence suggests that the function of NS5A includes abrogation of STAT-1 translocation, 29 suppression of STAT-1 phosphorylation 30 and repression of the protein kinase R protein kinase. [31] [32] [33] Because of its important function in controlling HCV replication, many molecules have been designed to target NS5A, some of which have exhibited promising treatment outcomes in clinical research. 34, 35 Other potential mechanisms of the anti-HCV effects of TRIM22 should be evaluated in future research.
We performed experiments demonstrating that a single mutation (K to R) of NS5A can all be ubiquitinated, which implies that multiple ubiquitination sites might appear in NS5A (Supplementary Figure 3) . At present, it is unclear which lysine in NS5A is ubiquitinated by TRIM22. The sequence of the HCV virus is constantly changing in the host. 36 Therefore, a large HCV mutation repertoire exists in every HCV patient. sites and the resistance to IFNa, next generation sequencing should be used to determine the mutation status of NS5A at a population level because HCV has a highly dynamic mutational profile. 37 Different time points should also be taken into consideration, and the association between the mutational profile and therapy should then be assessed. We will address those questions in a future study.
In this study, we observed that TRIM22 is induced after IFNa treatment and functions to degrade NS5A and, in turn, suppress HCV replication. Overall, our study indicates that TRIM22 has a novel anti-HCV effect during IFNa therapy in chronically HCV-infected patients and that this effect is mediated by the ubiquitination of NS5A.
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